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Differential splicing of COL4AS mRNA in kidney and white blood cells:
A complex mutation in the COL4A5 gene of an Alport patient deletes the
NC1 domain. PCR conditions were optimized to amplify the COL4A5
eDNA from lymphoblasts and kidney tissue. Sequencing of the
COL4A5 mRNA isolated from the kidney of an Alport syndrome
patient revealed two differences with the published sequence. One
divergence, the insertion of an 18 bp sequence between exon 11 and 10
of the COL4A5 mRNA added two Gly-X-Y triplets to the COL4A5
sequence and was subsequently found in the mRNA of four normal
kidney mRNA samples. This sequence was absent in all white blood
cell RNA samples sequenced by us, indicating tissue specific splicing
with the presence of an additional exon in kidney COL4A5 mRNA. This
finding of differential splicing of COL4A5 mRNA in kidney and white
blood cells might affect the use of white blood cell mRNA for the
analysis of Alport mutations. Second, a complex mutation was detected
in the mRNA from the AS patient introducing a premature stop codon
in the message, deleting part of the triple helical domain and the
complete NC domain. The mother of the patient was shown to be
heterozygous for this mutation.
Alport syndrome (AS) is an X-linked dominant disease char-
acterized mainly by a progressive nephritis with hematuria. The
clinical picture is heterogenous with a variable age of end-stage
renal disease, and a variable association with ocular lesions and
deafness. At the ultrastructural level the disease is character-
ized by the patchy splitting of the lamina densa of glomerular
basement membrane. A lack of fixation of antibodies to colla-
gen type 4 chains (a3-5) is also sometimes observed.
Genetic analysis maps the AS locus to chromosome Xq22
[1—31. This region carries the COL4A5 gene [4] and subsequent
analysis detected different point mutations as well as larger
deletions in the COL4A5 gene of AS patients [5—11]. Linkage
analysis did not show evidence for heterogeneity at the locus
level, although the presence of a second AS gene close to the
COL4AS gene could not be excluded [121. Analysis of the
different COL4A5 alleles might, however, permit a correlation
of the clinical pathology with specific mutations in the COL4A5
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gene and investigation of the molecular mechanisms underlying
AS pathology.
The COL4AS gene spans more than 100 kb of the human
genome and contains more than 50 exons. Mutation screening
strategies based on Southern hybridization or exon sequencing
are rather insensitive or very time consuming. As an alternative
cDNA sequencing was developed based on the illegitimate
transcription of the COL4A5 gene in lymphoblasts [6, 13, 14],
since the transcription of the COL4AS gene appears to be
restricted to the kidney [15]. This implicitly requires the illegit-
imately transcribed mRNA to be a bona fide version of the
normal tissue specific mRNA, which is normally accepted to be
the case.
To investigate this hypothesis and to allow a large scale
screening for AS mutations, we optimized conditions to amplify
the COL4A5 cDNA in six overlapping fragments from po1y(A)
RNA isolated from white blood cells and from kidney tissue.
Comparison of the sequences of the mRNA of both tissues
strongly suggests alternative splicing with the presence of an
additional exon in the COL4A5 mRNA in kidney, which is
absent in white blood cell mRNA. The presence of the addi-
tional exon was then confirmed on a second Alport kidney
sample, three normal kidney samples and a primary culture of
kidney cells. Sequencing of the cDNA from an AS patient
showed a complex deletion/missense mutation which was also
detected in the DNA of the mother of the patient.
Methods
Patients and samples
The patient was a 2.5-year-old boy with macroscopic hema-
tuna without fever or pain and a proteinuna of 300 mg/day, with
a mildly decreased creatinine clearance of 72 ml/min/l .73 m. A
kidney biopsy at that time showed focal sclerosing lesions.
Alterations of the basement membrane, characteristic for Al-
port's disease, were not seen at electron microscopy of the only
glomerulus available. With continued hematuria a second bi-
opsy was taken two years later and this showed minimal
mesangial proliferation, with negative immunohistology. A
third biopsy was taken at the age of 8, when the child became
clinically deaf due to a perception defect. Now interstitial foam
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Table 1. Collagen 4A5 PCR primer list
Forward primers Reverse primers
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Fig. 1. Strategy for amplification of the COL4A5 cDNA by PCR. A scheme of the COL4AS protein according to [7]. The aminoterminal signal
peptide, the carboxyterminal NC! domain and the collagenous domain are shown. Interruptions of the triple helical domain by non-collagenous
sequences are indicated by vertical bars and cross hatched regions. The localization of the six amplified fragments (with their length in bp between
brackets) is shown with the localization of the primers (arrows) and the nested primers (arrowheads). The boundaries of the fragments are indicated
on the bar representing the COL4A5 cDNA with the numbering according to [7].
cells were found. The material for electron microscopy con-
tained no glomeruli. The renal function deteriorated progres-
sively, and hemodialysis was started at the age of 13. He was
transplanted with a cadaver kidney one year later. At that time
a nephrectomy was performed, and fragments of this kidney
were used for molecular biological investigation. The child died
two and a half months later from an Epstein Barr virus-related
transplant lymphoma.
A kidney biopsy of his mother at the age of 28, for persistent
hematuria and proteinuria after the birth of her son, showed
focal sclerosis with the presence of interstitial foam cells.
Immunohistochemical examination was negative. Electron mi-
croscopy of the specimen showed a thin basement membrane
but no lesions characteristic for Alport's disease. However,
recutting of the same glomeruli at the time of renal failure of her
son revealed the typical basket wave appearance of the base-
ment membrane, in some areas not present in the original
sections. From the patient a fragment of the puncture biopsy
was available for molecular biological investigation.
Four other kidney samples were obtained. One sample was
obtained by nephrectomy at the moment of transplantation of
an Alport patient. Two samples were normal tissue obtained by
nephrectomy for renal carcinomas, and the fourth sample of
normal tissue was obtained by nephrectomy for transitional cell
carcinoma of the renal pelvis.
Kidney cells were obtained by a direct culture of normal
kidney tissue obtained by nephrectomy for renal cell carci-
noma.
White blood cells where obtained by fractionation of periph-
eral blood with dextran 500. EBV transformed cells of Alport
patients and normal controls were established according to
standard procedures and maintained in DME:F12 (1:1) contain-
ing 4% Ultroser (Gibco).
Reverse transcription PCR
RNA was extracted from cultured cells and from tissues
using the acid guanidinium thiocyanate-phenol method [161.
Poly(A) RNA was isolated from 40 pg of total RNA using
oligo(dT)25 Dynabeads (Dynal,AS). The poly(A) RNA was
eluted from the beads and first strand eDNA was synthesized
using 200 units M-MLV reverse transcriptase and 0.5 pg
oligo(dT) primer in 20 xl of the buffer recommended by the
manufacturer. The reaction proceeded for one hour at 37°C and
was stopped by heating to 95°C for five minutes. As a control
for contamination with genomic DNA, 10 pg of RNA were
digested with 1 U of RNase-free DNase for 15 minutes at 37°C
prior to eDNA synthesis and PCR.
Six pairs of nested primers were selected according to the
published COL4A5 sequence [7] (Table 1, Fig. 1). To allow for
solid phase sequencing of the PCR products, one primer of each
second set was biotinylated at its 5' end. PCR was performed in
100 p1 of 0.01% gelatme, 50 mi KCL, Tris-HCI 10 mM, 1.5 mM
MgCI2, 100 ps dNTP's, 2.5 units Taq DNA polymerase and 25
p primer in the first PCR and i p in the second.
One microliter of cDNA synthesis mix was used for the first
PCR, which consisted of a five minute denaturation at 95°C and
+. Frag.1(996)
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five cycles of 45 seconds at 95°C, 10 minutes at 58°C, 1.5
minutes at 72°C, followed by 25 cycles of 45 seconds at 95°C, 45
seconds at 60°C and 1.5 minutes at 72°C. A total of 1.5 pi of the
first PCR product was used in a second amplification for 30
cycles of 45 seconds at 94°C, 45 seconds at 60°C and 80 seconds
at 72°C. Negative controls included PCR with water instead of
the cDNA, with 2 pg of the original RNA sample and with 2 sg
of the DNase-treated RNA sample, both without cDNA syn-
thesis reaction, PCR products were first resolved on 1% agarose
gels and visualized with ethidiumbromide. All samples were
then sequenced [17] on an automated ALF (Pharmacia) se-
quencer using a solid phase approach and specific FITC-labeled
primers.
Sequences were analyzed using the Intelligenetics Suite Ver
5.4 software.
DNA analysis
DNA was isolated from kidney samples using proteinase K
followed by a phenol-chloroform extraction.
Two primers (F: 5'-TGTCGTCAlTTGCTGTGGAT and R:5'-
CA1TFCCTACCTGGAGTCCT) flanking exon 10 were chosen
according to the published sequence [18] generating an amplified
fragment of 171 bp. The fragment was separated on a 0.7% agarose
gel, purified using the Magic DNA Clean-up System (Promega),
ligated into Smal cut pGEM-3Z vectors and transformed into
DH5a. Ten insert-containing clones were isolated and sequenced.
Results
Comparison of COL4A5 cDNA derived from lymphoblasts
and kidney
The possibility to use mRNA isolated from lymphoblasts [19]
to screen for COL4AS mutations should allow a more compre-
hensive screening for mutations. Therefore, the amplification of
4664 bp of the COL4A5 cDNA starting from RNA isolated from
EBV transformed white blood cells in six overlapping nested
PCRs was optimized (Fig. 2). This covers part of the 7S domain
and the complete triple-helical and carboxyterminal NC 1 do-
mains of the collagen aS(IV) molecule. The PCR products
obtained from EBV transformed cells of a normal control were
completely sequenced using a solid phase approach, and the
sequence corresponded exactly to the one published by Zhou et
al [7] proving amplification of the correct cDNA.
When the COL4A5 cDNA sequence was determined using
the same strategy but starting with poly(A) RNA isolated from
a kidney biopsy obtained from an Alport patient, two divergent
regions were observed compared to the published consensus
sequence.
First an additional 18 bp was observed between bp 3992 and
3993 of the published sequence [7]. A careful analysis of the
fluorescent trace obtained by the automated sequencer also
showed the additional presence of the consensus sequence
(about 20 to 30% of the signal) (Fig. 3, bottom). The PCR and
sequencing were repeated on a second cDNA sample obtained
independently from the same RNA with identical results (not
shown). The insertion of 18 bp occurred exactly at the boundary
between two exons and conserved the reading frame of the
COL4A5 mRNA. In addition the Gly-X-Y repeat of the collag-
enous triple helical domain was preserved by the insertion of
two Gly-X-Y triplets. To exclude contamination with genomic
Fig. 2. PCR amp ILfication of the COL4A5 cDNA. COL4A5 cDNA was
synthesized from lymphoblasts mRNA and amplified in six overlapping
fragments according the strategy outlined in Fig. 1. Abbreviation is M,
size markers, with the size of the fragments indicated in bp at the left
side of the picture. Lane I to 6: PCR products obtained by the
amplification of the COL4AS cDNA fragments I to 6, respectively.
DNA as a possible source of PCR artifacts, the experiment was
repeated with DNase-treated RNA, with identical results. Fur-
thermore, when the original RNA sample and the DNase-
treated RNA sample were used as negative controls without
prior reverse transcription, no PCR product was obtained
(results not shown). Taken together, this strongly suggested
that the insertion was a splice variant rather than a PCR artifact
or a disease causing mutation. To analyze this further, RNA
was isolated from an additional Alport kidney sample, three
normal kidney samples and one cultured kidney cell sample,
and the corresponding domain was amplified and sequenced.
The COL4A5 sequence of these kidneys and the kidney cell
culture showed an identical insertion of 18 bp (Fig. 3). This
result was also confirmed by sequencing the PCR products
generated by three other independent cDNA synthesis reac-
tions and by sequencing the complementary strand (results not
shown). Identical results were obtained when only one PCR
was performed directly with the second set of primers on
kidney eDNA, further excluding PCR artifacts. Sequencing of
the same domain of the COL4A5 mRNA amplified from seven
different EBV transformed cell lines and from four samples of
white blood cells showed the consensus sequence (without the
18 bp insertion) in each of the cases.
Detection of a new complex AS mutation
In the second divergent region 7 bp (bp 4059 to 4065 of the
sequence according to Zhou et al [7]) appeared to be deleted
and three point mutations occurred (Fig. 4). The deletion of 7 bp
changed the reading frame and introduced a premature stop
codon 30 bp downstream of the mutation, resulting in a message
for a truncated collagen a5(IV) molecule lacking the NC1
domain (Fig. 4). This sequence was also confirmed using a
second independent eDNA sample. The remaining sequence
corresponded exactly to the published COL4AS sequence.
This complex mutation occurred in exon 10 (numbering
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Deduced amino acid sequence G P P G R P G
consensus nucleotide sequence 5' GGTCCTCCTGnAGACCAG GTCTACCAGGTC,
Fig. 3. Variant splicing of COMAS mRNA in kidney and white blood cells. The COL4A5 cDNA sequence of EBV cells (upper), of a normal
kidney tissue (middle) and of the kidney of an Alport patient (bottom) is shown. An 18 bp insertion between exon 10 and 11 codes for two Gly-X-Y
triplets, conserves the reading frame of COL4A5 mRNA and is flanked by consensus splice signals. The boundary between exon to and 11 is
indicated by a triangle; the 18 bp insertion is underlined. W = A + T; M = A + C. The sequence is read from 3' to 5'.
G G I KG E KG N PG 0 PG L PG L PG L
A: 5-(4035)GGAGGTATTAAAGGAGAGAAGGGAAATCCAGGCCAAGCTGt3GCTACCTGGGTTGCCTGGT TTGA
111111111111 liii I I I III 1111111111 I 11111 11111111111111111111 liii
11111 I 11111 ill 11111 III LI 1111111 LIII LI liii 1111111111111111 1111
B: 5-(4035)GGAGGTATTAAAGGAGAGAAGGGAA CCTTCTTGGGCTACCTGGCTTGCCTGGT TTGAG G I KG E KG T FL G Y LAG LV *
Fig. 4. A complex COMAS mutation detected in an Alport patient. A. Wild type COL4A5 sequence with the amino acid sequence on top(numbering according to [7]). B. Sequence observed for the AS patient with the deduced amino acid sequence below. *The TGA stopcodon
introduced by the frameshift.
according to Zhou et a! [18]) of the COL4AS gene. Since only a
small needle biopsy (<10 mg) of the mother of the patient was
available to investigate the origin of this complex mutation, a
PCR was developed to amplify exon 10 of the COL4A5 gene.
DNA was isolated from the kidney biopsy of the mother and
exon 10 of the COL4A5 gene was amplified and subcloned. Ten
clones were isolated containing a total of 12 copies of the PCR
product. Sequencing detected six copies of wild type sequence
and six copies of the mutant type sequence, indicating that the
mother was heterozygous for a similar deletion in exon 10.
Discussion
Sequencing of the COL4A5 cDNA obtained by reverse
transcription PCR of kidney poly(A) RNA revealed two
divergent regions compared to the published sequence: an
insertion of 18 bp and a complex deletion/missense mutation in
exon 10.
The insertion shows all the properties of a variant exon: it is
inserted at the boundary of exon 11 and 10 (numbering accord-
ing to Zhou et a! [18]), the reading frame is kept intact and the
triple helical Gly-X-Y motif is conserved. The insertion is
unlikely to be a PCR artifact: it was observed in five indepen-
dent RT-PCR experiments with a normal kidney sample and
with four additional kidney samples, and the inserted sequence
is not derived from elsewhere in the COL4A5 cDNA. One
round of PCR with second primers generated the same se-
quence further arguing against an artifact generated by the
nested PCR. The 18 bp sequence is also not present in the
published intron sequences 3' of exon 11 and 5' ofexon 10 [18],
suggesting that the observation is not the result of a partial
splicing event. Identical results were obtained alter DNase
treatment of the RNA. PCR with the RNA or the DNase-treated
RNA as a template, resulted in the absence of any PCR
products showing the absence of any amplifiable template in the
RNA samples. This, taken together with the fact that the
remaining sequence corresponds exactly to the published
Nucleotide sequence of
kidney mRNA
deduced amino acid sequence
L P GP EG
I lilt I I 11111 11111111 I 11111 IIIliii till iii I Ill lii I ill liii
GGTCCTCCTGGGAGACCAGGTcCTACAGGTTTGMGGTCTACCAGGTCAGAAGGT
GP PGRPGPTGFQGLPGPEG
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cDNA sequence also excludes amplification of genomic DNA
as a source of this PCR product.
It should also be noted that within the mRNA sequence this
18 bp exon is flanked by consensus splice signals, This might
explain the loss of this exon in the white blood cell mRNA. The
published COL4A5 cDNA sequences were derived from pla-
cental and umbilical vein endothelial cDNA libraries [201 and a
library derived from a fibrosarcoma cell line [71, respectively,
and it is conceivable that in these sources a splicing pattern
occurs comparable to the one observed in white blood cells.
An 18 bp exon would be unusually short in a collagen gene
although non-fibrillar collagen genes do not follow the 54 bp rule
for the exons coding for the Gly-X-Y repeats [211. Thus far no
reports were made of variant splicing of the COL4AS gene and
the significance of the insertion of two Gly-X-Y triplets on the
association of a-chain monomers and on the cross linking of
different triple helices is not known. It has been argued that for
fibrillar collagens the triple helical domains have to be of the
correct identical length whereas in the case of type IV collagens
forming a flexible network this would be a less stringent
requirement. However, in one Alport patient the skipping of
exon 38 was reported leading to a deletion of nine Gly-X-Y
triplets and this deletion was suggested to be directly related to
the Alport pathogenesis in this patient [13]. Complex alternative
splicing generates at least four different forms of al(XIII)
mRNA and interestingly this alternative splicing also involves
exons coding for pure collagenous regions [22]. Differential
splicing was also reported for the COL6A2 and the COL6A3
genes [23], but this affected only the globular aminoterminal and
carboxyterminal domains of the type 6 collagen. Similarly
splice variants were described modifying the aminoterminal
domain of type II collagens [24].
Sequencing of this region of the COL4AS cDNA of the
kidney of the Alport patient reveals the presence of the con-
sensus sequence in addition to the major signal of the insertion.
This could be due to variant splicing within the same tissue,
possibly influenced by the complex mutation observed in the
exon downstream of the insertion (see further), or to the
presence of a higher number of white blood cells in the Alport
kidney. The observation of both sequences in two of four
kidney samples could support the latter hypothesis.
Reverse transcription PCR based on the illegitimate tran-
scription of genes in white blood cells is a powerful tool for the
detection of mutations in a number of disease genes and it has
been argued in a number of cases that the RNA processing was
identical in the specific tissue and in the white blood cells [13,
19, 25]. The variant COL4A5 sequence, which is most probably
the result of variant splicing, observed here in kidney compared
to white blood cells demonstrates that the results obtained with
white blood cell RNA should be interpreted with care, espe-
cially in the cases where no mutation is found.
The COL4A5 cDNA isolated from the kidney of the Alport
patient shows a complex mutation formed by a 7 bp deletion
and three nucleotide changes resulting in the generation of a
premature stop and deleting part of the triple helical domain and
the complete NCI domain. This mutation was inherited from
the mother. Deletions of the carboxyterminal part of the aS(IV)
molecule were already reported in several Alport patients [26,
27], and it is suggested that these mutations result in more
severe clinical manifestations compared to point mutations.
This is in accordance with the finding of a rather early deafness
and renal failure in the boy. The mother, however, is still having
adequate renal function at the age of 42.
In conclusion, variant splicing of COL4A5 was found in the
mRNA of kidney and white blood cells inserting a 18 bp exon
between exon 10 and 11 in the kidney mRNA, and a complex
mutation was detected in an Alport patient introducing a
premature stop codon. The mutation was inherited from the
mother.
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